254 related articles for article (PubMed ID: 36546625)
21. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE; Nahid P; Kurbatova EV; Goldberg SV; Bozeman L; Burman WJ; Chang KC; Chen M; Cotton M; Dooley KE; Engle M; Feng PJ; Fletcher CV; Ha P; Heilig CM; Johnson JL; Lessem E; Metchock B; Miro JM; Nhung NV; Pettit AC; Phillips PPJ; Podany AT; Purfield AE; Robergeau K; Samaneka W; Scott NA; Sizemore E; Vernon A; Weiner M; Swindells S; Chaisson RE;
Contemp Clin Trials; 2020 Mar; 90():105938. PubMed ID: 31981713
[TBL] [Abstract][Full Text] [Related]
22. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC; Phillips PPJ; Kurbatova E; Vernon A; Nahid P; Dawson R; Dooley KE; Sanne I; Waja Z; Mohapi L; Podany AT; Samaneka W; Savic RM; Johnson JL; Muzanyi G; Lalloo UG; Bryant K; Sizemore E; Scott N; Dorman SE; Chaisson RE; Swindells S;
Clin Infect Dis; 2023 Feb; 76(3):e580-e589. PubMed ID: 36041016
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
24. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
[TBL] [Abstract][Full Text] [Related]
25. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
[TBL] [Abstract][Full Text] [Related]
26. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
[TBL] [Abstract][Full Text] [Related]
27. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
[TBL] [Abstract][Full Text] [Related]
28. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Turkova A; Wills GH; Wobudeya E; Chabala C; Palmer M; Kinikar A; Hissar S; Choo L; Musoke P; Mulenga V; Mave V; Joseph B; LeBeau K; Thomason MJ; Mboizi RB; Kapasa M; van der Zalm MM; Raichur P; Bhavani PK; McIlleron H; Demers AM; Aarnoutse R; Love-Koh J; Seddon JA; Welch SB; Graham SM; Hesseling AC; Gibb DM; Crook AM;
N Engl J Med; 2022 Mar; 386(10):911-922. PubMed ID: 35263517
[TBL] [Abstract][Full Text] [Related]
29. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Otto-Knapp R; Edwards S; Kuchukhidze G; Kröger S; Häcker B; Bivol S; Yedilbayev A
Euro Surveill; 2024 Apr; 29(17):. PubMed ID: 38666403
[TBL] [Abstract][Full Text] [Related]
30. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
[TBL] [Abstract][Full Text] [Related]
31. Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Vanino E; Granozzi B; Akkerman OW; Munoz-Torrico M; Palmieri F; Seaworth B; Tiberi S; Tadolini M
Int J Infect Dis; 2023 May; 130 Suppl 1():S12-S15. PubMed ID: 36918080
[TBL] [Abstract][Full Text] [Related]
32. Pretomanid for tuberculosis: a systematic review.
Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
[TBL] [Abstract][Full Text] [Related]
33. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
[TBL] [Abstract][Full Text] [Related]
34. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
[TBL] [Abstract][Full Text] [Related]
35. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
[TBL] [Abstract][Full Text] [Related]
36. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
[TBL] [Abstract][Full Text] [Related]
38. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
39. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial.
Velayutham B; Jawahar MS; Nair D; Navaneethapandian P; Ponnuraja C; Chandrasekaran K; Narayan Sivaramakrishnan G; Makesh Kumar M; Paul Kumaran P; Ramesh Kumar S; Baskaran D; Bella Devaleenal D; Sirasanambati DR; Vasantha M; Palaniyandi P; Ramachandran G; Uma Devi KR; Elizabeth Hannah L; Sekar G; Radhakrishnan A; Kalaiselvi D; Dhanalakshmi A; Thiruvalluvan E; Raja Sakthivel M; Mahilmaran A; Sridhar R; Jayabal L; Rathinam P; Angamuthu P; Soorappa Ponnusamy K; Venkatesan P; Natrajan M; Prasad Tripathy S; Swaminathan S
Trop Med Int Health; 2020 Apr; 25(4):483-495. PubMed ID: 31944502
[TBL] [Abstract][Full Text] [Related]
40. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
